Bevacizumab gamma for treating wet age-related macular degeneration

Bevacizumab gamma is recommended as an option for treating wet age-related macular degeneration in adults, only if:

• the eye has a best-corrected visual acuity between 6/12 and 6/96

• there is no permanent structural damage to the central fovea

• the lesion size is 12 disc areas or less in greatest linear dimension

• there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes)

• the company provides it according to the commercial arrangement.

Use the least expensive option of the available treatments (including bevacizumab gamma, aflibercept, faricimab and ranibizumab). Take account of administration costs, dosages, price per dose and commercial arrangements. If the least expensive option is unsuitable, people with the condition and their healthcare professional should discuss the advantages and disadvantages of other treatments.

Only continue bevacizumab gamma treatment if an adequate response is maintained. Criteria for stopping should include persistent deterioration in visual acuity and anatomical changes in the retina.

These recommendations are not intended to affect treatment with bevacizumab gamma that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.